

SMT unveils Hydra TAVR device in Central Europe

15 September 2020 | News

This technology allows for precise placement of the valve and also ensures orthotopic deployment

SMT (Sahajanand Medical Technology Pvt Ltd), a global medical device company based in Mumbai, has launched the Hydra TAVR device in Central Europe.

Internationally renowned interventional cardiologists Prof. Marek Grygier and Prof. Maciej Lesiak deployed HYDRA successfully at Poland's Szpital Kliniczny Przemienienia Pańskiego centre.

Transcatheter Aortic Valve Replacement (TAVR) is an established treatment modality for patients who are at a high risk or unwilling to undergo open heart valve replacement surgery.

The Hydra aortic valve is a self-expandable nitinol based supra annular aortic system with a mechanism for recapturing of the valve during deployment. This technology allows for precise placement of the valve and also ensures orthotopic deployment.

Speaking about the successful launch, Marek Kurysz, Country Head of SMT Poland said, "This is a significant step forward for SMT in Central Europe. Structural Heart is really a team effort, thanks to Prof. Grygier and Prof. Lesiak for their trust, Prof. Lars Sondergaard, Dr. Ole DeBacker for their first class proctoring and the TAVI Research Centre (TRC) in Surat for their world class clinical back end support."